Biotechnology
JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao
SHANGHAI, June 4, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its new drugapplication (NDA) for the CAR-T cell immunotherapy product Car...
2025-06-05 09:04
2918
Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-06-05 08:23
2249
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-06-05 08:00
4197
Proto Axiom and St Vincent's Curran Foundation join forces to host Australia's largest medical pitch day
SYDNEY, June 5, 2025 /PRNewswire/ -- Proto Axiom, Australia's leading biotech incubator, and St Vincent's Curran Foundation unite to launch Challenger Pitch for Health, the nation's largest medical and biotech pitch event, in Sydney in March 2026. Challenger Pitch for Health will award $500,000 ...
2025-06-05 07:55
1863
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The a...
2025-06-04 20:00
2566
Elpis Biopharmaceuticals and Singapore General Hospital Enter Research Collaboration Agreement to Develop Next Generation Allogeneic CAR Technologies
Agreement focuses on advancing armored and bi-specific CAR-γδTs for AML and multiple myeloma LEXINGTON, Mass. and SINGAPORE, June 4, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announc...
2025-06-04 19:00
2447
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...
2025-06-04 08:00
6214
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific re...
2025-06-04 06:30
3722
ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis
TOKYO, June 3, 2025 /PRNewswire/ -- ThinkCyte, a life science company pioneering advanced AI-powered cell analysis and sorting technologies, today announced the pre-commercial launch of MorphoScan Cloud, its new cloud-based platform designed for flexible data access, faster processing, and advanc...
2025-06-03 23:34
1942
Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach
* Phase IIa study results of Rentosertib were published simultaneously in
NatureMedicine(IF = 58.7) and presented at the American
2025-06-03 22:27
2892
Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
* EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. * The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of p...
2025-06-03 14:00
2638
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for regis...
2025-06-03 09:00
1652
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea, June 1, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clini...
2025-06-02 10:22
2306
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical iso...
2025-06-02 09:00
2770
Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience
New solution improves protocol design, reduces patient- and site-burden,
accelerates recruitment, and delivers increased efficiencies for clinical
trials
SINGAPORE, June 2, 2025 /PRNewswire/ -- Medidata
2025-06-02 09:00
2109
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
NANJING, China, May 31, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide ...
2025-06-01 08:00
2951
CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world's first circular RNA drug being administrated in patients
SHANGHAI, May 30, 2025 /PRNewswire/ -- Shanghai CirCode Biomed Co. Ltd. (CirCode), an innovative biotech company pioneering circular RNA therapies, recently announced that its leading pipeline HM2002 received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FD...
2025-05-31 10:27
2938
Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
DA NANG, Vietnam, May 31, 2025 /PRNewswire/ -- May 9-11, 2025, Gene Solutions
2025-05-31 10:16
3997
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001
* Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications * Interim safety and pharmacokinetic data from BBT002-01 study anticipated in Q1 2026 * The clearance of BB...
2025-05-30 21:30
2912
Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration
JOHNSON CITY, Tenn., May 30, 2025 /PRNewswire/ -- Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central laboratory services. The two parties will jointly build a full-chain laboratory service system covering...
2025-05-30 05:05
2212
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 268 media titles]
2026-01-01 10:00
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
